Pfizer announces promising Phase 3 vaccine trial results | Burns & Wilcox

The vaccine trial reports an unexpectedly high success rate in preventing COVID-19 infection—more than 90 percent effective. Concerns are raised about the requirements that the vaccine be stored at about -75 degrees Celsius (-100 degrees Fahrenheit), around 50 degrees colder than any other vaccine currently in use in the U.S. Some states and hospital systems rush to purchase new freezers to accommodate the vaccine, creating potential supply shortages, and some experts warn of potential major glitches when frontline workers must handle large amounts of dry ice, which is also in short supply in many parts of the country.

Source: CNN